SRPT Sarepta Therapeutics Forecast, Technical & Fundamental Analysis
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders... Show more
SRPT is expected to report earnings to fall 65.30% to 22 cents per share on November 04
Q3'26
Est.
$0.22
Q2'26
Beat
by $0.42
Q1'26
Beat
by $2.17
Q4'25
Missed
by $2.37
Q3'25
Beat
by $0.57
The last earnings report on August 05 showed earnings per share of 63 cents, beating the estimate of 21 cents. With 837.12K shares outstanding, the current market capitalization sits at 1.91B.
A.I. Advisor
published General Information
General Information
a developer of treatments for life-threatening illnesses and viruses
A.I.dvisor indicates that over the last year, SRPT has been loosely correlated with RCKT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if SRPT jumps, then RCKT could also see price increases.
SRPT's RSI Indicator recovers from oversold territory
The RSI Oscillator for SRPT moved out of oversold territory on August 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In of the 36 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 04, 2026. You may want to consider a long position or call options on SRPT as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for SRPT just turned positive on August 06, 2026. Looking at past instances where SRPT's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
SRPT moved above its 50-day moving average on August 10, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SRPT crossed bullishly above the 50-day moving average on August 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SRPT advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRPT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SRPT broke above its upper Bollinger Band on August 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SRPT entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SRPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.251) is normal, around the industry mean (20.443). P/E Ratio (45.486) is within average values for comparable stocks, (24.270). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.844). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (1.031) is also within normal values, averaging (438.852).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
